LabCorp prenatal test a negative for Sequenom, says Maxim Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
MedAssets upgraded to Outperform from Market Perform at Leerink Leerink upgraded MedAssets to Outperform citing the pullback in shares since the Q2 results, the potential for improving volumes in Q3 and the company's total portfolio approach. The firm has a $26 price target for shares.